Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY22 results · Oct–Dec 2021
Astec LifeSciences reported revenue from operations of ₹173.35 crore (up 49.4% from Q3 FY21) and net profit of ₹24.75 crore (up 250.4% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 173.35 | 116.01 | +49.4% | 102.57 | +69.0% |
| Other income | 1.96 | 3.27 | −40.1% | 0.90 | +117.9% |
| Total income | 175.31 | 119.28 | +47.0% | 103.47 | +69.4% |
| Profit before tax | 33.21 | 11.28 | +194.5% | 12.18 | +172.7% |
| Net profit for the period | 24.75 | 7.06 | +250.4% | 9.08 | +172.7% |
| Attributable to shareholders of the company | 24.75 | 7.06 | +250.6% | — | — |
| EPS, basic (₹) | 12.63 | 3.61 | +249.9% | 4.63 | +172.7% |
| Net margin (%) | 14.3 | 6.1 | 8.8 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 173.35 | 116.01 | +49.4% | 102.57 | +69.0% |
| Other income | 1.96 | 3.27 | −40.1% | 0.90 | +117.9% |
| Total income | 175.31 | 119.28 | +47.0% | 103.47 | +69.4% |
| Profit before tax | 33.19 | 11.25 | +194.9% | 12.16 | +173.0% |
| Net profit for the period | 24.74 | 7.05 | +251.0% | 9.06 | +172.9% |
| EPS, basic (₹) | 12.63 | 3.60 | +250.8% | 4.63 | +172.9% |
| Net margin (%) | 14.3 | 6.1 | 8.8 |
Consolidated
- Filed with BSE
- 27 Jan 2022, 09:27 IST
- Board meeting
- 25 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2022, 09:27 IST
- Board meeting
- 25 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE